Gena Wang

want to confirm I heard it correct that the price for AMVUTTRA will be declined at the mid-single digit year-over-year

out of the 1,400 patients treated so far, will be over 50% of patients is a first-line patient

which one do you think it's a good benchmark for in vitro first quarter revenue

if you can share the key factors that impact your decision on pricing adjustment for AMVUTTRA

What is the learning there? Why immunogenicity data did not translate to clinical benefit

how often do you track pharmacies to maintain their inventory? And what additional color you can share regarding your estimate of the revenue

any latest thoughts regarding flu combo submission requirement? This is specifically regarding the FDA

What is the learning there? Why immunogenicity data did not translate to clinical benefit

how often do you track pharmacies to maintain their inventory? And what additional color you can share regarding your estimate of the revenue

What would it take for the FDA to remove the clinical hold? What kind of outcome that we deem to be okay

CMV, since now we've seen additional months of events accruing, should we still be able to see the final readout in the first half '25

do you think with your drug profile, do you think it could actually improve the eGFR over the longer treatment

If we look at the first quarter revenue and when we compare to the other CF launch in the past, how do you see this compared to the past

for the temporary pause, was that due to the -- so I don't know if you can give a little bit more color regarding what are the tolerability issue